The 2025 Lilly Pulitzer Sunshine Sale has up to 70% off activewear, dresses, sweaters, accessories, home decor, and more. This rare event happens twice a year—shop now before your favorites sell ...
Lilly Pulitzer’s Sunshine Sale is here, and it’s brimming with vibrant dresses, blouses, and more fashion finds up to 78 percent off. Whether you’re hoping to refresh your wardrobe with ...
Learn more. Guess what? Lilly Pulitzer just added a bunch of new styles to the 2024 Sunshine Sale, and they’re up to 70% ...
Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year. The maker of weight-loss drugs Mounjaro and Zepbound said sales of the drugs grew ...
In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...
On Oct. 30, Lilly told investors to expect 2024 revenue to land in a range between $45.4 billion and $46 billion. Sales of the company's diabetes and weight loss treatments are soaring but not ...
Jan 14 (Reuters) - Eli Lilly's (LLY.N), opens new tab stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the ...
Overall fourth-quarter sales are expected to be $13.5 billion, Lilly said in a statement of preliminary results, below the $14 billion average estimate of analysts surveyed by Bloomberg.
Eli Lilly’s (LLY) shares slumped over 8% on Tuesday after the company projected fourth-quarter sales of its weight-loss drug Zepbound and diabetes treatment Mounjaro to fall short of Wall Street ...
Eli Lilly shares climbed 32% last year but have slumped more than 16% since October after the company reported third quarter sales of the two drugs below Wall Street’s expectations, prompting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback